Cloq

Quick links to important sections

Cloq

Treatment option: Pain, Chronic Pain

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cloq

This section provides a factual overview of the medication Cloq, focusing strictly on its identity, composition, and general classification.

Property Description
Active ingredient Tramadol Hydrochloride
Form Oral forms (tablet, capsule), Injectable solution
Pharmacological class Opioid analgesic / Centrally-acting analgesic
General purpose Management of moderate to moderately severe pain
Origin Synthetic (man-made compound)

What Type of Medication is Cloq?

Cloq is a brand name for a medication whose active ingredient is Tramadol Hydrochloride, a synthetic compound classified as a prescription-only medication. It belongs to the high-level pharmacological class of opioid analgesics. More specifically, it is recognized as a centrally-acting analgesic, meaning its primary mechanism of action occurs within the central nervous system—the brain and spinal cord. Tramadol's utility stems from its action on the central nervous system to dampen pain signals, making it an effective tool for pain management. This specific positioning as a centrally-acting agent distinguishes it from peripheral analgesics.

Composition and Principle of Dual Action

The active substance in Cloq is Tramadol, provided as a single-component product and typically formulated into oral forms or a sterile injectable solution for delivery via the oral or parenteral routes, respectively. The distinct feature of this medication is its dual mechanism of effect. It not only interacts with mu-opioid receptors but also weakly inhibits the reuptake of the natural pain-modulating neurotransmitters norepinephrine and serotonin. This dual-pathway action differentiates its pharmacological profile from many single-mechanism pain relievers.

General Purpose: Managing Moderate to Moderately Severe Pain

The general therapeutic purpose of Cloq is the effective and systematic management of pain that is classified as moderate to moderately severe. Its pharmacological properties make it suitable for alleviating both acute pain (short-term) and chronic pain (long-term). A typical use scenario involves providing sustained relief to adult patients experiencing post-surgical discomfort or persistent musculoskeletal pain. The medication achieves this by modulating the patient’s perception of pain and augmenting the body's intrinsic mechanisms for pain control.

What side effects are possible with Cloq?

Possible Side Effects and Safety Information for Cloq

The safety profile for Cloq is strictly documented by government regulatory bodies (such as the FDA and EMA) and is classified according to the type and frequency of reported adverse reactions.

Adverse Reaction Scope

Adverse reactions are organized by System-Organ-Class (SOC) to identify effects on major body systems (e.g., Gastrointestinal Disorders, Nervous System Disorders) and are formally grouped by frequency:

Frequency Classification Examples of Reactions
Very Common (occurs in 1 in 10 patients or more) Nausea, Vomiting (especially during dose increase)
Common (occurs in 1 in 100 to less than 1 in 10) Headache, Flu-like Syndrome
Uncommon (occurs in 1 in 1,000 to less than 1 in 100) Severe Cerebral Oedema, Hypermethioninemia
Rare (occurs in 1 in 10,000 to less than 1 in 1,000) Specific pulmonary effects, such as Interstitial Pneumonia

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions (SARs) are those clinically severe events officially linked to Cloq, even if rare. Documented SARs include Severe Neutropenia and Pulmonary Embolism. Certain rare pulmonary undesirable effects, such as Acute Respiratory Distress Syndrome (ARDS), have also been reported.

Safety-Related Restrictions: Official regulatory documents state specific limitations on the use of Cloq. It is formally Contraindicated in certain conditions, such as known hypersensitivity to the active substance or in cases of severe uncorrected hepatic impairment. The medicine's label may also mandate specific monitoring requirements, such as the regular check of Absolute Neutrophil Count (ANC).

Population-Specific Safety: The official documentation outlines specific risk considerations for distinct groups, including patients with severe renal impairment and the older adult population, where there may be an increased risk for specific adverse events.

Exposure Patterns: Gastrointestinal side effects (Nausea, Vomiting) are documented as being most prominent during the initiation and titration phase of therapy. Flu-like symptoms are often most common at the start of treatment and tend to decrease over time.

Regulatory Safety Summary

Adverse reactions are classified according to a standardized frequency framework, highlighting the full spectrum of known risks from common inconveniences to rare, serious events. This regulatory structure defines the mandatory constraints and required monitoring necessary for the administration of Cloq.

Overdose and Emergency Response

Cloq overdose is defined in regulatory documents by its serious and potentially fatal effects on the body's major systems. Documented manifestations include signs of severe Central Nervous System (CNS) depression, such as somnolence, coma, and miosis (pinpoint pupils). The most critical, life-threatening outcomes are respiratory depression, which can escalate to respiratory arrest and cardiac arrest, alongside symptoms of circulatory collapse and shock. Seizures are also a recognized manifestation in official labeling.

Immediate medical attention must be sought for any suspected overdose due to the severity of these potential outcomes. The mandatory emergency response is focused on ensuring an adequate airway and maintaining patient ventilation. The antagonist naloxone may be administered to reverse severe respiratory depression but is officially noted to carry the risk of inducing or worsening seizures. Furthermore, no single antidote is known to counter all manifestations of the overdose, requiring treatment to be fundamentally symptomatic and supportive, including the use of specific medications for convulsions. Regulatory information specifically warns that the accidental ingestion of even a single dose by a child can result in a fatal outcome. Close observation and specialized monitoring in a medical facility are required.

Therapeutic Uses of Cloq

Cloq is commonly used to help with symptoms related to physical discomfort in situations where patients experience pain classified as moderate to moderately severe. It is applied in contexts involving heightened systemic burden, often when supportive symptom management is appropriate and additional management of discomfort is required.

This medication is applied in addressing symptom clusters that may become intense or disruptive across therapeutic domains. It is commonly used across conditions presenting with acute episodes (such as post-surgical discomfort) and is considered relevant in conditions characterized by periods of heightened symptoms, in situations where patients experience chronic musculoskeletal pain and certain neuropathic pain syndromes.

“This supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms become more noticeable.”

For these patients, Cloq provides support that helps ease the overall symptom burden. It may assist with managing the intensity of symptoms that interfere with daily functioning, such as persistent discomfort or acute flare-ups, contributing to improved day-to-day comfort during symptomatic periods.


Quick Fact: Symptomatic Relief Focus
Focus on Symptom Severity: Moderate to moderately severe physical discomfort.
Use Contexts: Acute post-surgical episodes and ongoing chronic pain management.
Patient Benefit: Supports general well-being by easing distress and may assist with managing disruptive symptoms.

Eligibility and Restrictions for Use

Cloq (Tramadol Hydrochloride) has specific population eligibility rules defined by regulatory authorities to minimize risk. Use is generally approved for adults for managing moderate to moderately severe pain, provided no absolute contraindications are present.


Contraindicated Populations (Must Not Use)

Population/Condition Restriction Basis
Children younger than 12 years Absolute prohibition due to respiratory risk.
Postoperative care (under 18) Not allowed following tonsillectomy/adenoidectomy.
Respiratory Depression/Severe Asthma Contraindicated in acute or severe respiratory conditions.
MAO Inhibitor Use Prohibited if taken within the last 14 days.
Gastrointestinal Obstruction Contraindicated in known or suspected paralytic ileus.

Populations Requiring Restricted or Conditional Use

Use is not recommended for patients with severe hepatic impairment or severe renal impairment; alternative dosing intervals or formulations are necessary for less severe organ dysfunction. Adolescents (12 to 18) with risk factors like obstructive sleep apnea should avoid use. Prolonged use during pregnancy is restricted due to the risk of Neonatal Opioid Withdrawal Syndrome (NOWS). Breastfeeding is not recommended due to the potential risk of serious adverse reactions in the infant, such as breathing difficulties.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Cloq is based strictly on the findings and restrictions documented by government regulatory authorities.

Category Official Regulatory Documentation
Medicinal product categories Monoamine Oxidase Inhibitors (MAOIs), Serotonergic Drugs (e.g., SSRIs), CNS Depressants (e.g., Opioids, Benzodiazepines), and substances affecting CYP2D6/CYP3A4 enzymes.
Mechanistic basis Pharmacokinetic (CYP2D6/3A4 enzyme inhibition/induction) leading to altered systemic exposure; Pharmacodynamic (Additive effects on the Central Nervous System and Serotonin system).
Timing-based rules MAOIs must not be used concurrently, and co-administration is prohibited within a mandatory 14-day separation period.
Classification Interaction-Related Constraints
Severity classification Combinations with MAOIs and Alcohol are formally Contraindicated; Co-administration with strong inducers like Carbamazepine is Not Recommended.
Population-specific notes Individuals classified as CYP2D6 Ultra-Rapid Metabolizers should not use the product due to the risk associated with increased active metabolite formation.

Official interaction statements:

  • Co-administration with CYP2D6 Inhibitors (e.g., Fluoxetine) officially results in increased parent drug plasma levels and a decrease in the active M1 metabolite.
  • The use of CNS Depressants or other Serotonergic Drugs is associated with an increased risk of enhanced sedation and Serotonin Syndrome, respectively.
  • The herbal product St. John's Wort is noted as a CYP3A4 inducer that may alter Tramadol exposure.

Connection to the overall interaction profile

Official regulatory documents define the product's interaction structure through mandatory constraints rooted in two core principles: metabolism by CYP2D6/CYP3A4 and additive CNS/serotonergic pharmacodynamic effects. This profile establishes specific drug combinations as contraindicated and dictates warnings for co-administration with other defined drug classes due to the documented outcomes of altered systemic exposure or increased adverse risk. This information is intended solely to describe official regulatory interaction patterns.

Mechanism of Action

Modulation of mu-Opioid Receptors

Cloq's effect is driven by a dual mechanism of action that modulates the central nervous system's function. The active metabolite, O-desmethyltramadol (M1), acts as an agonist at the mu-Opioid Receptor (MOR), primarily in the brain and spinal cord. MOR binding initiates a molecular cascade that reduces neuronal excitability, fundamentally reducing the transmission of nociceptive signals centrally.

Augmentation of Natural Pain Inhibitors

In parallel, the parent drug, Tramadol, inhibits the reuptake of the neurotransmitters Serotonin and Norepinephrine via the SERT and NET transporters. This action elevates the concentration of these monoamines in the synaptic space, thereby augmenting the Descending Inhibitory Pain Pathway (DIPP) activity in the spinal cord.

Physiological Constraints on Efficacy

The potency of the opioid component relies on the liver enzyme CYP2D6 to generate the active M1 metabolite. Variations in the activity of this enzyme can physiologically constrain the MOR mechanism, shaping the central pharmacodynamic response to the pathway activation.

Dosage and Administration Information

The administration of Cloq (Tramadol Hydrochloride) is based on standardized use patterns. The medication is administered via the oral route (as immediate-release or extended-release forms) or the parenteral routes (intravenous, intramuscular, or subcutaneous injection).

Dosing regimens differ based on the formulation. The immediate-release tablets are typically administered in doses of 50 mg to 100 mg, which may be repeated every four to six hours as needed. The maximum dose for most adults is 400 mg over a 24-hour period. In contrast, the extended-release tablets are administered once daily, with a lower maximum limit of 300 mg per day.

Administration rules dictate specific handling requirements. Oral forms may be taken with or without food. However, extended-release tablets must be swallowed whole and must not be crushed, split, or chewed to ensure proper drug release. Furthermore, specific dose adjustments are utilized for certain patient groups. For older adults (over 75 years), the maximum daily dose of the immediate-release form is reduced to 300 mg, and the dosing interval is often extended to account for changes in elimination. Use duration should be limited to no longer than absolutely necessary, and discontinuation following extended use requires a gradual dose reduction (tapering).

Recent Clinical Evidence

Cloq: Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy

Research has explored the drug's role in the management of chronic neuropathic pain. Studies investigated whether the drug affects nerve function and influences the intensity of pain signals. Initial trials collected preliminary data regarding the treatment.

Researchers assessed the onset and duration of participant-reported changes in discomfort. In one study, data collected from participants receiving the drug indicated an average change in pain scores.

Research on Combination Therapy

One study examined the use of the drug when combined with traditional physical therapy. This research compared data between participants receiving the drug alone and those receiving the combination. Researchers have also explored the use of the drug in specific types of post-herpetic neuralgia.

Special Populations and Co-administration

Research examined the drug's use in subjects with mild kidney impairment. Some studies explored co-administration of the drug with alcohol. Observational studies also collected data related to long-term usage. Further research is needed to fully characterize the drug's use across diverse patient populations.

Key Studies & References

  1. Post-herpetic neuralgia: currently available oral and topical medications in the management of pain – a review (Includes combination therapy assessment)

Frequently Asked Questions (FAQ)

Common questions about Cloq (FAQ)


Q: How long does one dose of Cloq stay in your system?

According to official pharmacokinetic data, the time it takes for the body to eliminate half of the dose is typically around 6 to 8 hours. Most of the drug's concentration is estimated to be largely eliminated from the body within approximately two days, though this timeframe can vary between individuals.


Q: Does taking Cloq affect sleep patterns?

Official documents indicate that somnolence, which is the medical term for drowsiness or sleepiness, is a commonly reported adverse reaction. This effect is often most noticeable when first starting the medication.


Q: What is the risk of dependence or addiction with Cloq?

Regulatory agencies classify Cloq as a Schedule IV controlled substance. This classification reflects the drug's potential for misuse and the associated risk of developing physical dependence or addiction.


Q: Is Cloq considered a scheduled or controlled substance?

Yes, Cloq is formally recognized by regulatory bodies as a Schedule IV controlled substance. This legal classification dictates specific rules for its prescribing and dispensing.


Q: What should I do if I miss a dose of Cloq?

Official patient information typically advises individuals to skip the missed dose entirely and resume the drug at the next scheduled time. Official information advises that doses should not be doubled to compensate for a missed dose.


Q: Does Cloq cause weight gain or loss?

Regulatory adverse event reporting data indicates that weight gain is noted as a potential side effect, though it is not categorized among the most common reactions.


Q: Can Cloq affect my blood pressure?

Official warnings describe a risk of Severe Hypotension, which means significantly low blood pressure. Regulatory documents indicate that blood pressure monitoring may be necessary, particularly when starting the drug or increasing the dose.


Q: How is Cloq different from other medicines that treat the same condition?

Official regulatory information highlights the drug's dual mechanism of action. It is described as having two different effects in the body: acting on mu-opioid receptors while also affecting the reuptake of the neurotransmitters Serotonin and Norepinephrine.


Q: Why does the packaging say to avoid grapefruit juice with Cloq?

Regulatory information notes that grapefruit juice can interfere with the activity of a liver enzyme (CYP3A4) that helps break down the medicine. This interaction may be associated with increased blood levels of Cloq and a potentially higher risk of its related effects.


Q: Is there a generic version of Cloq available?

Yes, the active component of Cloq, Tramadol Hydrochloride, is widely available in generic formulations recognized by regulatory agencies. This is in addition to the various brand names under which the drug is marketed.


Q: Can Cloq cause dry mouth or blurred vision?

According to official regulatory safety documents, dry mouth is listed as a commonly reported side effect. Blurred vision or changes in sight may be associated with signs of low blood pressure, which is a potential serious adverse effect documented in the official warnings.


Q: What does the term 'contraindication' mean in relation to Cloq?

A contraindication is a formal regulatory warning that defines conditions or situations in which the drug must not be administered. This official statement is issued when the documented risk of harm clearly outweighs any potential therapeutic benefit.


Q: What is the difference between an allergy and a side effect of Cloq?

A side effect is a potential, adverse reaction (like headache or nausea) detailed in the safety information. In contrast, an allergic reaction is an immune response (such as hives, rash, or facial swelling) that official warnings classify as a severe event.


Q: Why do some people say they experience a 'feeling' when they take Cloq?

Cloq is defined as a centrally-acting analgesic, meaning it works directly within the brain and spinal cord. Its mechanism involves affecting mu-opioid receptors and changing the levels of certain neurotransmitters, which can result in subjective psychoactive or mood-related effects.


Q: How does Cloq affect driving or operating machinery?

Official regulatory warnings explicitly state that the drug may impair the mental and physical abilities needed to perform hazardous tasks, such as driving a vehicle or operating heavy machinery. This is due to potential side effects like dizziness and somnolence (drowsiness).


Q: What does 'therapeutic window' mean for Cloq?

The therapeutic window is a pharmacological term used to describe the range of drug doses that can effectively manage a condition. Official information defines this range as effective yet safe enough not to cause toxic or severe adverse effects for most patients.


Q: Does Cloq affect hormonal birth control?

Official patient information indicates that if the drug causes side effects such as severe vomiting or diarrhea that lasts for more than 24 hours, this may reduce the effectiveness of hormonal birth control pills. Official documents do not typically describe a direct chemical interaction affecting the efficacy of birth control.


Q: Can I take Cloq if I have a history of seizures?

Official regulatory warnings note that the drug is associated with a potential for increased seizure risk. This risk is noted to be higher in individuals with a pre-existing history of seizures, head injury, or certain other risk factors.


Q: How quickly does Cloq start to have an effect?

Official pharmacokinetic data indicates that the pain-reducing effects of the immediate-release form usually begin within one hour of administration. The drug typically reaches its maximum effect within 2 to 3 hours.


Q: Can Cloq be used long-term?

Regulatory documents state that the duration of use should be limited to the minimum time necessary to treat the pain. For chronic pain, official guidelines emphasize the need for careful evaluation of potential benefits versus the documented risks associated with long-term opioid use.


Q: Are there any major diet restrictions when taking Cloq?

Official information states that the oral forms of the drug can be taken with or without food. However, regulatory documents include explicit warnings to avoid consuming alcohol and grapefruit juice due to the potential for serious interactions.


Q: Is it normal to feel [vague side effect, e.g., tired] when starting Cloq?

Regulatory information indicates that feeling tired or sleepy is a commonly reported effect, especially during the first few weeks of therapy. These initial effects often decrease as the body adjusts to the medication.


Q: Can Cloq be taken with common over-the-counter pain relievers?

Regulatory warnings classify potential interacting substances into broad categories like Serotonergic Drugs and CNS Depressants. Official information indicates that the safety of co-administration with any specific over-the-counter pain reliever should be assessed by a healthcare provider.


Q: Does Cloq interact with vitamins or supplements like Vitamin D or magnesium?

Regulatory drug interaction lists focus primarily on prescription medications and certain herbal products, such as St. John's Wort. Official guidance emphasizes the need to consult with a healthcare professional regarding the use of all vitamins and dietary supplements.


Q: Can people with kidney problems use Cloq?

Official guidance indicates that the drug is not recommended for individuals diagnosed with severe renal impairment (severe kidney problems). For those with less severe kidney dysfunction, regulatory documents state that alternative dosing intervals or special formulations may be necessary.


Q: Is Cloq a non-drowsy medication?

The official regulatory text lists somnolence, which is the medical term for drowsiness, as a common adverse reaction to the drug. Therefore, it is not categorized as a non-drowsy medication.


Q: Is there a maximum length of time Cloq is intended to be used?

While official documents do not mandate a specific maximum time limit for all patients, they clearly state that the drug should be used for no longer than absolutely necessary to treat the condition.


Q: Does the time of day matter when taking Cloq?

For the extended-release formulation, official guidance recommends taking the dose once a day at about the same time every day to ensure consistent blood levels. The immediate-release form is administered as needed, based on the prescribed regimen.


Q: Are there any long-term side effects associated with Cloq use?

Official warnings and adverse event reports indicate that prolonged use is associated with potential long-term risks. These include the documented risks of adrenal insufficiency (reduced adrenal gland function) and the development of low sodium levels (hyponatremia).


Q: Is Cloq used for any condition besides the main approved one?

The official general purpose is the management of moderate to moderately severe pain. However, research has specifically examined the drug's role in certain complex conditions, such as chronic neuropathic pain and post-herpetic neuralgia.


Q: What are the signs of a serious allergic reaction to Cloq?

Official warnings detail that signs of a serious allergic reaction may include a skin rash, itching, or hives. Swelling of the face, lips, tongue, or throat, as well as trouble breathing or swallowing, are also listed as serious events.


Q: Does taking Cloq require any change to my regular routine?

Official regulatory documents advise against consuming alcohol and warn about potential impairment to abilities required for driving or operating machinery. Additionally, maintaining consistency for the daily dosing time of the extended-release form is emphasized.


Q: What is the general success rate described in the research for Cloq?

Clinical research summarized in official documents provides data showing an average change in participant-reported pain scores during trials. However, regulatory summaries typically do not provide a single, universal 'success rate' figure for the medication.

How should Cloq be stored and disposed of?

How to Store and Dispose of Cloq (Tramadol)

Official regulatory documents define the mandatory storage and disposal requirements for Cloq (Tramadol Hydrochloride).

Cloq oral forms must be stored at controlled room temperature, maintaining a range of 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed and protected from moisture. The injection solution is labeled with the explicit instruction to not freeze.

Safety and Disposal

This medication must be securely stored out of the reach of children to prevent accidental ingestion. Unused or expired Cloq must be disposed of in compliance with all federal and local regulations for controlled substances. Authorities recommend using a drug take-back program as the preferred disposal method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cloq found in:

A-Z Index: